MedImmune today announced that Peter Greenleaf has been appointed as the company's new President, effective immediately. Mr. Greenleaf will report to Tony Zook, who remains responsible for MedImmune on AstraZeneca's Senior Executive Team.
Since joining the company in 2006, Peter has been a major contributor to the growth of MedImmune. He has overseen the development of the global marketing and portfolio organizations, as well as managing the broader commercial, corporate development and strategy functions. He has also been accountable for MedImmune Ventures, a corporate development investment group. In addition to being a member of the MedImmune Executive Team, Peter has led the cross-functional Brand Management Team and been a member of the Product Development Committee.
Greenleaf stated: "I am very excited about the future of MedImmune – and the role that biologics will play in achieving AstraZeneca's long term success. I look forward to working closely with my colleagues from across the broader company."
Prior to MedImmune, Greenleaf was at Centocor, Inc., where he served as franchise vice president, responsible for sales, marketing, strategic planning and business development. Previously, he served in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc. He has a bachelor of science degree from Western Connecticut State University and a master's degree in business administration from St. Joseph's University.
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com